advances in treatment of hbv january_03_marzano.pdf · 2015-02-03 · advances in treatment of hbv...
TRANSCRIPT
Advances in treatment of HBVAlfredo Marzano
San Giovanni Battista Hospital
University of Turin
Italy
I
Outline
• General background
• Therapy
• Aims
• Strategies
• Efficacy
• Drugs and virus
• Clinical results
• Summary
I
Background
HBVHBsAg+ > 400 millions
antiHBc+ > 2 billions
8 different genotypes.
High replicative activity : 1011-12 virions/daily
High Mutations rate: 1 every 100,000
Acute
InfectionChronic
Infection Cirrhosis Death
1. Torresi, J, Locarnini, S. Gastroenterology. 2000.
2. Fattovich, G, Giustina, G, Schalm, SW, et al. Hepatology. 1995.
3. Moyer, LA, Mast, EE. Am J Prev Med. 1994.
4. Perrillo, R, et al. Hepatology. 2001.
5%-10% of
chronic HBV-
infected
individuals1
Liver
Failure(Decomp.)
30% of chronic
HBV-infected
individuals1
• >90% of infected
children progress
to chronic disease
• <5% of infected
immunocompetent
adults progress to
chronic disease1
23% of patients
decompensate
within 5 years of
developing
cirrhosis 3
Liver
Cancer
(HCC)
Chronic HBV is the
6th leading cause of
liver transplantation
in the US 4
Liver
Transplantation
Inactive
carrier
3%/yr
3%/yr
Natural History of CHBDisease
Natural history of CHBVirological aspects (infection)
Adapted by Kim HJ & Lok ASF. Hepatology 2006
Anti-HBe
HBeAg
HBV DNA
ALT
ReactivationInactive
carrier state
Immune
clearance
Immune
tolerant
HBsAg+ (overt) HBsAg- (OBI)
e+CHB
e-CHB
HBV DNA
IC ACIC
qHBsAg H
Bs
Ag
(lo
g IU
/mL
)
Immune tolerance (7)
e+ active CHB (25)
e seroconversion (17)
e- active CHB (46)
e- inactive CHB (22)
Chan HL et al. Hepatology 2010
117 chronic hepatitis B patients
followed for 9916 months; number of visits 17 (8–49)
Cirrhosis
Gaia, J Hepatol 2011
* Oliveri, WJG 2008
Staging
Liver biopsy and Fibroscan
6*Inactive
OBI
Immunotollerant
Chronic Hepatitis
I
Therapyaims
Antiviral Therapy in HBVGoals
HBV DNA
IU
qHBsAg
IU
HBeAg
AC > 2000 > 1000 Pos/neg
IC < 2000 <1000 neg
neg <100 neg
OBI neg neg neg
STOP
Evolution
Cirrhosis (regression)
Portal hypertension
Liver transplantation
HCC
Mortality
I
TherapyStrategies
Therapeutic strategies
Curative (defined time)
Suppressive (NUC) (undefined time)
PEG
NUC (e+)
PEGSuppressive (NUC)
induction
Curative
Suppressive (NUC) PEG
ConsolidationCurative
Immune modulation (theraputic vaccines)
This topic falls outside my time
I
TherapyEfficacy
PEG-IFNPeg-IFN in HBeAg-positive
Marcellin, Gastroenterology 2009
e+
e-
50%
HBsAg
clearance
J Hepatology 2012
Better response in genotype non-D/E
Marengo & Marzano
Antivir Ther 2013
100%
TDF
Marengo & Marzano
APT 2014
ETV
Pangenotypic
I
TherapyDrugs and Virus
Why the mono-therapy is effective?
Virus and Drugs characteristics
Suppression vs. cure:
viral biology is the basis
Kieffer TL, et al. J Antimicrob Chemother. 2010;65:202-212.
HCV6 genotypes
(No Latent Reservoir)
HCV RNA
Definitive Viral
Clearance
Host DNA
Host cell
Nucleus
cccDNA
Long-Term
Reduction of Viral
Replication to
Lowest Possible
Level
HBV 10 genotypes
(Latent Reservoir)
cccDNA = covalently closed circular DNA.
Suppression Cure
Long-time cccDNA
“Low “ replicative space
Drugs
Pharmacologic barrier
Intracellular drugs levels and resistance
I generation (high drug levels)
Low toxicity, medium potency
Time
Intr
acell
ula
r C
on
cen
trati
on
s
Drug level required
to overcome WT
virus
Drug toxicity
thresholdLAM
Drug level required
to overcome
“resistant” virus
Modified from Moyle G, et al. Drugs. 1996
Drug level required
to overcome
“resistant” virus
Time
Intr
acell
ula
r C
on
cen
trati
on
s
ADF
Drug level required
to overcome WT
virus
Drug toxicity
threshold
Drugs
Pharmacologic barrier
Intracellular drugs levels and resistance
II generation (low drug levels)
High toxicity, medium potency
Modified from Moyle G, et al. Drugs. 1996
Drug level required
to overcome
“resistant” virus
Modified from Moyle G, et al. Drugs. 1996
Time
Intr
acell
ula
r C
on
cen
trati
on
s
Drug level required
to overcome WT
virus
Drug toxicity
thresholdTDF, ETV
Drugs
Pharmacologic barrier
Intracellular drugs levels and resistance
III generation (high drug levels)
Low toxicity, high potency
Drug levels, Genetic barrier and the virus
ADV LAM ETV, TDF (?)
HBV
HCV
W
W
WW
W
W
W
W
WW
WW
W
W
W
W
WW
W
W
W
W
WW
WW
W
WM
on
o-th
era
py
III
II
I
M
III
II
I
MM
MM
MM
MM
MM
MM
M
M
HCV
W
W
WW
W
W
W
W
WW
WW
W
W
HCV
W
W
WW
W
W
W
W
WW
WW
W
W
M
Mo
no
-the
rap
y
MM
M
MMM
hours days
HCV RNA+
HBV
W
W
WW
W
W
W
W
WW
WW
W
W
HBV
W
W
WW
W
W
W
W
WW
WW
W
W
M
M
M
Replicative spaceNative
XX
XX
X
months years
HBV DNA- (II-III generation)
29
70
18
67
0
11
49
0.5
38
0.20
24
Genetic Barrier
Incidence of Resistance in NUC-naïve Patients
0
20
40
60
80
LAM ADV LDT ETV TDF
Pati
en
ts (
%)
17
3 1.2?4
01.2
1.20
adapted from EASL HBV Guidelines, J Hepatol 2012
1st generation
2nd generation
3rd generation
*Collation of currently available data – not from head-to-head studies
0 0
I
TherapyClinical Results
Can we reach clinical results
with the NUCs?
Marcellin P; The Lancet 2013
Regression of histological cirrhosis with TDF
N=57N=57
* Median time of long-term biopsy: 6 years (range: 3–7 years)
Reversal of fibrosis/cirrhosis with ETV
Chang TT, Hepatology 2010
Marengo, & Marzano Antiviral Therapy 2013
Decompensation Death
* 2 CH
CH
Cirrhosis
Clinical experience with III gen NUCs:
Entecavir 100 pts (55 compensated cirrhosis)
0
20
40
60
80
100
0 12 24 36 48 60 72 84 96 108 120 Months
27 24 19 9 4 3
80%
2127 15 8 4
27 26 23 2
0
14 92427 21 18 14
12%
EV progression
EV regression
0
20
40
60
80
100
0 12 24 36 48 60 72 84 96 108 120
Patients
at risk80 78 74 62 45 3380 6778 56 39
8%
EV progression
Changes of esophageal varices (EV) in
compensated cirrhotics treated with LAM±TDF for 10 years
No varices at baseline (n=80)
Lampertico et al, submitted 2013
F1 varices at baseline (n=27)
Overall, EV worsening rate per year: 0.9%*
* 6 of 7 progressors (86%) had either LMV-R and/or HCC
Decompensated cirrhosis
Mutimer DJ, Gut 2012
2429 pts
Prophylaxis of hepatitis B recurrence after LTCholangitas, Am J Transpl 2013
Excellent results but……
HCC remains the residual problem
Expected annual risk in Europe ( untreated) 0.2% (CH) -2% (Cirrhosis)
0
1
2
3
4
Liaw
(2004)
1.5%
HC
C p
er
year
(%)
Papatheod.
(2010)
HCC rates in NUC-naïve cirrhotic patients
long-term responding to NUC (LAM-exp)
2.4%2.5%
Papatheod.
(2011)
2.8%
Kurokawa
(2012)
Aghemo A et al, J Hepatol 2012
211 81Num. of pts: 62 42
LAM LAMDrug: LAM LAM
RCT ReviewStudy: Retrosp. Retrosp.
3 yrs 2 yrsFollow-up: 6 yrs 5 yrs
Clinical experience with ETV:
HCC in 472 (gen B-C) vs 1143 untreated patients
Hosaka, Hepatology 2012
1.4% y
0.5% y
HCC rates in ETV or TDF treated CHB pts
European multicenter study
0%
10%
20%
30%
40%
50%
Cu
mu
lative
pro
ba
bili
ty o
f H
CC
0 1 2 3 4 5
Years of NUC therapy
HCC rates/yr in chronic hepatitis: 0.5%
HCC rates/yr in compensated cirrhotics: 4.2%
21%
(N=1231 patients, 54% naive, 55% TDF, 39 months follow-up)
Papatheodoridis G & Lampertico P et al, AASLD 2013
Compensated Cirrhosis
Chronic hepatitis 5%
4% y
1% y
LT for HBV-related cirrhosis in US and Europe
Decompens.vs
HCC
Van Bommel, Liver Int 2013; Burra & Marzano, J Hepatol 2013
HBV …. too
Summary